Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.

Arquivos de neuro-psiquiatria 20121001

An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.

Science translational medicine 20120926

Age-related changes in the pattern electroretinogram of normal and glatiramer acetate-immunized rats.

Investigative ophthalmology & visual science 20120921

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

The New England journal of medicine 20120920

The 'poison chair' treatment for multiple sclerosis.

The New England journal of medicine 20120920

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Neurology 20120911

Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.

Journal of the neurological sciences 20120815

[Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate].

Revista de neurologia 20120801

Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20120701

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Drugs 20120618

Decreased microglial activation in MS patients treated with glatiramer acetate.

Journal of neurology 20120601

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response.

European journal of neurology 20120601

Management of children with multiple sclerosis.

Paediatric drugs 20120601

Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.

Current medical research and opinion 20120501

Immunotherapies in neurologic disorders.

The Medical clinics of North America 20120501

Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.

Journal of the neurological sciences 20120415

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20120401

The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.

Clinical reviews in allergy & immunology 20120401

Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.

Journal of neuroimaging : official journal of the American Society of Neuroimaging 20120401

Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.

European journal of clinical pharmacology 20120401

Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.

Journal of neuroimmunology 20120401

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Expert review of neurotherapeutics 20120401

[2012: Update on diagnosis and treatment of multiple sclerosis].

Deutsche medizinische Wochenschrift (1946) 20120401

Glatiramer acetate induced hepatotoxicity.

Current drug safety 20120401

Immunization with A91 peptide or copolymer-1 reduces the production of nitric oxide and inducible nitric oxide synthase gene expression after spinal cord injury.

Journal of neuroscience research 20120301

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20120301

Glatiramer acetate reverts stress-induced alterations on adult neurogenesis and behavior. Involvement of Th1/Th2 balance.

Brain, behavior, and immunity 20120301

Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.

Advances in therapy 20120301

Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.

Multiple sclerosis (Houndmills, Basingstoke, England) 20120201

Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

Journal of the neurological sciences 20120115

Adherence to treatment in multiple sclerosis.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20120101

Comparative long-term preclinical safety evaluation of two glatiramoid compounds (glatiramer Acetate, Copaxone(R), and TV-5010, protiramer) in rats and monkeys.

Toxicologic pathology 20120101

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.

Pharmacogenomics 20120101

The effectiveness of glatiramer acetate in clinical practice: an observational study.

Revista de neurologia 20120101

Magnetization transfer imaging of acute black holes in patients on glatiramer acetate.

Frontiers in bioscience (Elite edition) 20120101

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.

Journal of medical economics 20120101

Early diagnosis, monitoring, and treatment of optic neuritis.

The neurologist 20120101

Impact of inflammation on brain volume in multiple sclerosis.

Archives of neurology 20120101

Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.

Clinical therapeutics 20120101

Glatiramer acetate anaphylaxis: detection of antibodies and basophil activation test.

Journal of investigational allergology & clinical immunology 20120101

Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a longitudinal study.

Neuroimmunomodulation 20120101

Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.

Neurologia i neurochirurgia polska 20120101

[Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101

Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.

International journal of molecular sciences 20120101

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.

BMC neurology 20120101

Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.

Investigative ophthalmology & visual science 20111121

Contact dermatitis induced by glatiramer acetate.

Multiple sclerosis (Houndmills, Basingstoke, England) 20111101

[Embolia cutis medicamentosa (Nicolau syndrome) after glatiramer acetate injection].

Actas dermo-sifiliograficas 20111101

Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.

Journal of autoimmunity 20111101

Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate.

Clinical neurology and neurosurgery 20111101

Early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Multiple sclerosis (Houndmills, Basingstoke, England) 20111101

Persistence with biologic therapies in the Medicare coverage gap.

The American journal of managed care 20111101

[Multiple sclerosis: current therapies and future perspectives].

Nihon rinsho. Japanese journal of clinical medicine 20111101

Glatiramer acetate elevates cell production in the mature retinal pigment epithelium.

Visual neuroscience 20111101

[Expressional changes of Th1 and Th2 cells in retina of a rat glaucoma model vaccinated by Cop-1].

Zhonghua yi xue za zhi 20111025

Natalizumab for relapsing remitting multiple sclerosis.

The Cochrane database of systematic reviews 20111005

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study.

Journal of neurology 20111001

Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110901

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Journal of neurology 20110901

Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis.

Scandinavian journal of immunology 20110901

Clinical consequences of MRI activity in treated multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20110901

Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.

Scandinavian journal of immunology 20110901

MS Forum/MS Over the Past 17 Years.

International MS journal 20110901

Glatiramer acetate (GA), the immunomodulatory drug, inhibits inflammatory mediators and collagen degradation in osteoarthritis (OA) cartilage.

Osteoarthritis and cartilage 20110901

Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.

Advances in therapy 20110901

Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.

European journal of neurology 20110801

[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].

Revista de neurologia 20110801

Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica.

Medical hypotheses 20110601

Recent insights into the mechanism of action of glatiramer acetate.

Journal of neuroimmunology 20110601

Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis.

Expert review of neurotherapeutics 20110601

Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.

Journal of managed care pharmacy : JMCP 20110601

Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.

Arquivos de neuro-psiquiatria 20110601

The Brazilian database on pregnancy in multiple sclerosis.

Clinical neurology and neurosurgery 20110501

Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study.

Multiple sclerosis (Houndmills, Basingstoke, England) 20110501

Glatiramer acetate attenuates neuropathic allodynia through modulation of adaptive immune cells.

Journal of neuroimmunology 20110501

Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis.

The Journal of pharmacology and experimental therapeutics 20110501

Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs.

Journal of neuroimmunology 20110501

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

CNS drugs 20110501

Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20110501

Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.

The American journal of managed care 20110501

Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.

Journal of the neurological sciences 20110415

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.

Neurology 20110405

Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.

Journal of neuroimmunology 20110401

[Partial adrenocorticotropin hormone deficiency associated with multiple sclerosis].

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110401

A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Journal of neurology 20110301

Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate.

Journal of neuroimmunology 20110301

Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.

Pharmacogenomics 20110301

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Journal of immunology (Baltimore, Md. : 1950) 20110215

The therapeutic equivalence of complex drugs.

Regulatory toxicology and pharmacology : RTP 20110201

Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.

Medical hypotheses 20110201

Expression and functional activity of chemokine receptors in glatiramer acetate-specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate.

Human immunology 20110201

Qualitative spectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110201

[Current treatment of multiple sclerosis].

Lege artis medicinae : uj magyar orvosi hirmondo 20110201

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.

European journal of neurology 20110101

Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.

Experimental neurology 20110101

Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.

European neurology 20110101

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Annals of neurology 20110101

Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.

European neurology 20110101

Current disease-modifying treatment of multiple sclerosis.

The Mount Sinai journal of medicine, New York 20110101

[Rare and clinically relevant adverse reactions following subcutaneous administration of glatiramer acetate].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

BMC neurology 20110101

Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.

European neurology 20110101

The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.

Journal of medical economics 20110101

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

PloS one 20110101

Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.

PloS one 20110101

Glatiramer acetate treatment increases stability of spinal synapses and down regulates MHC I during the course of EAE.

International journal of biological sciences 20110101

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.

BMC neurology 20110101

Anaphylactic reaction after injection of glatiramer acetate (Copaxone®) in patients with relapsing-remitting multiple sclerosis.

European neurology 20110101

Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.

PloS one 20110101

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].

Molekuliarnaia biologiia 20110101

[State of antioxidant system in patients with multiple sclerosis during therapy].

Biomeditsinskaia khimiia 20110101

The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.

Journal of neuroimmunology 20101215

Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.

Journal of neurology 20101201

A method for evaluating treatment switching criteria in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20101201

Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population.

Multiple sclerosis (Houndmills, Basingstoke, England) 20101201

Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.

The American journal of pathology 20101201

Translational research in neurology and neuroscience 2010: multiple sclerosis.

Archives of neurology 20101101

Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.

CNS drugs 20101101

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.

Journal of neurology 20101101

Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: role of IGF-2.

Journal of neuroimmunology 20101008

Pharmacoeconomic considerations in the treatment of multiple sclerosis.

Drugs 20100910

Therapy of multiple sclerosis in children and adolescents.

Clinical neurology and neurosurgery 20100901

Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20100901

The identity problem.

Nature biotechnology 20100901

A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

Archives of neurology 20100901

Reversible alopecia associated with glatiramer acetate.

Archives of neurology 20100901

[Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].

Neurologia (Barcelona, Spain) 20100901

Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.

Journal of neuroimmunology 20100825

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Drugs 20100820

Modified protocol for desensitization to glatiramer acetate.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20100801

Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis.

Dermatology online journal 20100615

[Glatiramer acetate in patients with clinically isolated multiple sclerosis syndrome: PreCISe study].

Der Internist 20100601

Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20100601

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

Clinical therapeutics 20100601

Glatiramer acetate for multiple sclerosis.

The Cochrane database of systematic reviews 20100512

Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.

Expert opinion on drug metabolism & toxicology 20100501

[Diagnosis and therapy in multiple sclerosis].

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20100501

Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.

Brain research 20100414

Novel anti-inflammatory and neuroprotective agents for Parkinson's disease.

CNS & neurological disorders drug targets 20100401

Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.

Clinical immunology (Orlando, Fla.) 20100401

Improved muscle strength and mobility in the dy(2J)/dy(2J) mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate.

Neuromuscular disorders : NMD 20100401

Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20100401

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.

Clinical therapeutics 20100401

The double-edged sword of autoimmunity: lessons from multiple sclerosis.

Toxins 20100401

Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.

Journal of neuroimmunology 20100330

[Pharmacological treatment of multiple sclerosis].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20100311

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.

Current medical research and opinion 20100301

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Multiple sclerosis (Houndmills, Basingstoke, England) 20100301

Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis.

Journal of neuroimmunology 20100226

Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.

Multiple sclerosis (Houndmills, Basingstoke, England) 20100201

Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study.

Multiple sclerosis (Houndmills, Basingstoke, England) 20100201

Glatiramer acetate immune system augmentation for peripheral nerve regeneration in rat crushed sciatic nerve model.

The Journal of bone and joint surgery. American volume 20100201

Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.

The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20100201

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

Neurology 20100105

[Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].

Revue neurologique 20100101

Effects of methylprednisolone and glatiramer acetate on nitric oxide formation of cytokine-stimulated cells from the rat oligodendroglial cell line OLN-93.

Neuroimmunomodulation 20100101

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.

Experimental neurology 20100101

[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].

Duodecim; laaketieteellinen aikakauskirja 20100101

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.

Journal of medical economics 20100101

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.

BMC neurology 20100101

Medication adherence with disease modifying treatments for multiple sclerosis among US employees.

Journal of medical economics 20100101

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.

Health and quality of life outcomes 20100101

Allergy workup in immediate-type local reactions to glatiramer acetate.

Journal of investigational allergology & clinical immunology 20100101

[Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.

Journal of neurology, neurosurgery, and psychiatry 20091201

Restoring immune suppression in the multiple sclerosis brain.

Progress in neurobiology 20091201

Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.

CNS & neurological disorders drug targets 20091201

Do interferon beta-1b and glatiramer acetate grow brain?

The Lancet. Neurology 20091201

Health and quality of life in patients with relapsing multiple sclerosis: making the intangible tangible.

Journal of the neurological sciences 20091201

Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.

Journal of the neurological sciences 20091201

Early treatment: PreCISe-ly what the patient needs.

Journal of the neurological sciences 20091201

Current therapeutic recommendations in multiple sclerosis.

Journal of the neurological sciences 20091201

Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.

Journal of neuroimmunology 20091130

Glatiramer acetate treatment in PPMS: why males appear to respond favorably.

Journal of the neurological sciences 20091115

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

Neurology 20091110

Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone).

Journal of the European Academy of Dermatology and Venereology : JEADV 20091101

Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.

Journal of neural transmission (Vienna, Austria : 1996) 20091101

Serum levels of CXCL13 are elevated in active multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20091101

Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.

Current opinion in ophthalmology 20091101

Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy.

Multiple sclerosis (Houndmills, Basingstoke, England) 20091101

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Lancet (London, England) 20091031

Inhibition of experimental autoimmune uveitis by amino acid copolymers.

Journal of neuroimmunology 20091030

Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in experimental autoimmune encephalomyelitis.

Journal of neuroimmunology 20091030

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

The Lancet. Neurology 20091001

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.

Multiple sclerosis (Houndmills, Basingstoke, England) 20091001

Treatment of multiple sclerosis: role of natalizumab.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001

The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

Neurology 20090922

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.

Journal of the neurological sciences 20090915

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.

Multiple sclerosis (Houndmills, Basingstoke, England) 20090901

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Journal of managed care pharmacy : JMCP 20090901

[Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].

Neurologia (Barcelona, Spain) 20090901

Adherence of adolescents to multiple sclerosis disease-modifying therapy.

Pediatric neurology 20090801

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Multiple sclerosis (Houndmills, Basingstoke, England) 20090801

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.

Vojnosanitetski pregled 20090701

Cyclophosphamide therapy in pediatric multiple sclerosis.

Neurology 20090616

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Neurology 20090609

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20090601

Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Expert review of pharmacoeconomics & outcomes research 20090601

Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes.

Cell research 20090501

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.

Advances in therapy 20090501

Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46-62.

Autoimmunity 20090501

Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report.

Multiple sclerosis (Houndmills, Basingstoke, England) 20090401

Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate.

Cellular and molecular life sciences : CMLS 20090401

Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.

Neurology 20090317

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.

Neurology 20090303

Ameliorative effect of PN-277 on laser-induced retinal damage.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20090301

Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.

Irish journal of medical science 20090301

Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment.

European journal of neurology 20090301

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

European journal of neurology 20090301

The glatiramoid class of immunomodulator drugs.

Expert opinion on pharmacotherapy 20090301

[Therapy of multiple sclerosis].

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20090301

Glatiramer acetate positively influences spinal motoneuron survival and synaptic plasticity after ventral root avulsion.

Neuroscience letters 20090213

The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20090201

Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis.

European journal of neurology 20090201

Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.